Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin.
 
Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected to fare after years of Herceptin domination in the HER2-positive space. KOLs discuss how Roche’s Perjeta will be used in the future and whether the APHINITY trial results will change prescribing habits. Experts also give their views on whether the launch of Puma Biotechnology’s Nerlynx in the US has been successful. HER2-negative/HR-positive space, experts provide insights on Pfizer’s first-to-market CDK4/6 inhibitor, Ibrance, and whether Novartis’ Kisqali and Eli Lilly’s Verzenio are succeeding in taking a slice of the market.

Top takeaways:
Biosimilar trastuzumab has been launched in Europe. How do KOLs view these products and will patient switching from the branded product become commonplace? 
Perjeta is approved as an adjuvant therapy for HER2-positive disease in the US. How do KOLs perceive the APHINITY trial results and will they impact prescribing? 
Despite its US launch, Nerlynx has received a negative opinion in Europe. How do US KOLs view Nerlynx’s launch and how will this product be used going forward? 
How successful have the Kisqali and Verzenio launches been? And can Pfizer’s Ibrance retain its position as the preferred CDK4/6 inhibitor? 
How could the alpha specific PI3 kinase inhibitors, alpelisib and taselisib be positioned in the treatment paradigm? KOLs offer their views on these agents. 
Lynparza is now available as a therapy for BRCA-mutated, HER2-negative breast cancer. How is this product currently being prescribed and will usage evolve in the future? 

Marketed therapies:
Herceptin (trastuzumab; Roche) 
Kadcyla (ado-trastuzumab emtansine; Roche) 
Perjeta (pertuzumab; Roche) 
Tykerb/Tyverb (lapatinib; Novartis) 
Nerlynx (neratinib; Puma Biotechnology) 
Afinitor (everolimus; Novartis) 

Pipeline therapies:
margetuximab (MGAH 22; MacroGenics) 
alpelisib (BYL 719; Novartis) 
taselisib (GDC 0032; Roche) 
ipatasertib (GDC 0068; RG 7440; Roche) 
entinostat (SNDX 275; Syndax) 
talazoparib (BMN 673; Pfizer) 
Zejula (niraparib; Tesaro/Merck & Co.) 
veliparib (ABT 888; AbbVie) 

Ongoing Benefits:
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWords guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage. 

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update. 

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the reports publication date. 

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

For more details visit link: https://www.aarkstore.com/healthcare/960277/breast-cancer-kol-insight-2018

Category: Healthcare Market Research
Aarkstore Enterprise
+91 9987295242 | [email protected] | aarkstore.com